AGN News and Press, Allergan plc

2024-03-27 17:08:02 ET About to begin a phase 2b/3 multinational study of Ifenprodil Algernon Pharmaceuticals is a drug repurposing company. They're a phase 2 clinical stage company advancing a drug called Ifenprodil for idiopathic pulmonary fibrosis, but also as a potential thera...

2024-03-27 17:08:02 ET A stroke can be a devastating and debilitating event for an individual and their family, and a major burden on the health care system. Over 15 million people suffer strokes every year, and 85% of those have some form of disability as a result. Stroke-related cos...

2024-03-27 17:08:02 ET Stocks to Invest in: Healthcare Focused on the disease areas of stroke, idiopathic pulmonary fibrosis (IPF) & chronic cough, and chronic kidney disease Algernon is a drug re-purposing company that investigates safe, already approved drugs, inclu...

2024-03-27 17:08:02 ET Hopeful that lead compound will be found to reduce severity and duration of covid-19 infection Algernon Pharmaceuticals is a clinical stage drug repurposing company. On March 6th, 2020, the company announced that it was going to explore the potential of usin...

The Hague, March 19, 2024 - Aegon today announces it is exercising its right to redeem EUR 700 million of 4% fixed-to-floating subordinated notes. The redemption of these grandfathered Tier 2 securities will be effective as of April 25, 2024, when the aggregate principal amount of EUR 700 million...

The Hague, March 1, 2024 - Aegon announces today that its Board of Directors intends to nominate Lard Friese for re-election as Executive Director and CEO at the Annual General Meeting of Shareholders (AGM) on June 12, 2024, for a further four years. Mr. Friese began his tenure as the CEO of ...

Please click here to access all 2H 2023 results related documents. The Hague, March 1, 2024 - IFRS results Net result of EUR 0 million with operating result offset by realized losses on investment portfolio; net loss of EUR 199 million for the full-year Operating result of...

The Hague, December 8, 2023 - Aegon has entered into an agreement with its largest shareholder, Vereniging Aegon , to partially participate in Aegon’s current EUR 1.5 billion share buyback program. The repurchase of shares from Vereniging Aegon will commence as soon as Aegon has repurc...

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...

Please click here to access all 3Q 2023 Trading Update related documents The Hague, November 16, 2023 - Continued commercial momentum in US business and increased capital generation Operating capital generation before holding funding and operating expenses increases by 16% compare...